경피증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 적응증별, 지역별, 부문별 예측(2025-2030년)

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,401,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,813,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,637,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

경피증 치료제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 경피증 치료제 세계 시장 규모는 2025-2030년 동안 CAGR 5.0%를 기록하며 2030년까지 34억 4,000만 달러에 달할 것으로 예측됩니다. 시장 성장의 배경에는 브랜드 의약품, 제네릭 의약품, 시판 의약품을 포함한 저분자 치료 등 적응증 외로 사용되는 다양한 치료제가 출시되고 있기 때문입니다.

다양한 적응증과 약물이 혼재되어 있기 때문에 시장은 여러 진입자들에 의해 세분화되어 있으며, Roche는 생물학적 제제 면역억제제, Actemra/Loactemra, 셀셉트, 리툭산 등에서 압도적인 점유율을 차지하고 있으며, Pfizer와 Eli Lilly는 시장의 주요 기업입니다. 예측 기간 동안 Boehringer Ingelheim, Corbus Pharmaceuticals, Fibrocell을 포함한 신규 진입 업체들이 이 시장에서 기존 업체들의 점유율을 조금씩 잠식할 것으로 예상됩니다.

경피증 치료제 시장은 개발 단계에 있습니다. 적응증 추가 승인은 시장 진입 기업이 채택하는 가장 일반적인 전략 중 하나입니다. 예를 들어, 바이엘의 리오시구아토는 이전에 PAH에 사용되었지만 현재 SSc와 관련된 발가락 궤양 치료제로 임상시험 중입니다. 이 전략은 제약 산업에 유리하며, 높은 개발 비용을 상쇄하고 이미 개발되어 시장에 존재하는 하나의 분자로부터 더 큰 이익을 얻을 수 있기 때문에 다른 제약 회사들도 이 전략을 따르고 있습니다.

경피증 치료제 시장 보고서 하이라이트

• 면역억제제 부문은 2024년 27.4%의 최대 점유율을 차지했으며, 예측 기간 동안 우위를 유지할 것으로 보입니다.
• 면역억제제에 대한 높은 선호도는 이 약제군과 관련된 유리한 상환 시나리오로 인해 시장 점유율 우위를 유지하고 있습니다.
• 전신성 경피증 적응증이 주요 시장 점유율을 차지하고 있으며, 고가의 면역억제제 사용으로 인해 더욱 확대될 것으로 보입니다.
• 2024년 북미 경피증 치료제 시장에서 미국 시장은 90.6%의 점유율을 차지했습니다. 경피증 치료제 시장의 지속적인 성장을 뒷받침하는 것은 희귀질환 치료제에 대한 상환 상황의 발전과 더불어, 적응증 확대 및 퍼스트 인 클래스 치료제의 출시가 예상됩니다.
• 경피증에 대한 적응증 외 치료에 제네릭 의약품과 바이오시밀러가 많이 사용되고 있는 것이 주요 원인입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 경피증 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 경피증 치료제 시장 : 약물 종류 비즈니스 분석

• 약물 종류 시장 점유율, 2024년과 2030년
• 약물 종류 부문 대시보드
• 시장 규모와 예측과 동향 분석, 약물 종류별, 2018-2030년
• 면역억제제
• 포스포디에스테라제 5 억제제-PHA
• 엔도텔린 수용체 길항제
• 프로스타사이클린 유사체
• 칼슘 채널 차단제
• 진통제
• 칼슘 채널 차단제
• 기타

제5장 경피증 치료제 시장 : 적응증 비즈니스 분석

• 적응증 시장 점유율, 2024년과 2030년
• 적응증 부문 대시보드
• 시장 규모와 예측과 동향 분석, 적응증별, 2018-2030년
• 전신경화증
• 국소성 경피증

제6장 경피증 치료제 시장 : 약물 종류에 의한 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • F. Hoffman La-Roche Ltd
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Emerald Health Pharmaceuticals
  • Sanofi
  • Cytori Therapeutics Inc.
  • Chemomab
  • Corbus Pharmaceuticals Holdings, Inc.
  • Calliditas Therapeutics AB

ksm

영문 목차

영문목차

Scleroderma Therapeutics Market Growth & Trends:

The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company's share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Scleroderma Therapeutics Market Report Highlights:

• The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years
• High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
• Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
• The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Scleroderma Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Scleroderma Therapeutics Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Immunosuppressors
  • 4.4.1. Immunosuppressors Market, 2018 - 2030 (USD Million)
• 4.5. Phosphodiesterase 5 inhibitors - PHA
  • 4.5.1. Phosphodiesterase 5 inhibitors - PHA Market, 2018 - 2030 (USD Million)
• 4.6. Endothelin Receptor Antagonists
  • 4.6.1. Endothelin Receptor Antagonists Market, 2018 - 2030 (USD Million)
• 4.7. Prostacyclin Analogues
  • 4.7.1. Prostacyclin Analogues Market, 2018 - 2030 (USD Million)
• 4.8. Calcium Channel Blockers
  • 4.8.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
• 4.9. Analgesics
  • 4.9.1. Analgesics Market, 2018 - 2030 (USD Million)
• 4.10. Calcium Channel Blockers
  • 4.10.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Scleroderma Therapeutics Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Systemic Scleroderma
  • 5.4.1. Systemic Scleroderma Market, 2018 - 2030 (USD Million)
  • 5.4.2. Morphea
    • 5.4.2.1. Morphea Market, 2018 - 2030 (USD Million)
  • 5.4.3. Linear
    • 5.4.3.1. Linear Market, 2018 - 2030 (USD Million)
• 5.5. Localized Scleroderma
  • 5.5.1. Localized Scleroderma Market, 2018 - 2030 (USD Million)
  • 5.5.2. Diffuse Systemic Sclerosis
    • 5.5.2.1. Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
  • 5.5.3. Limited Cutaneous Systemic Sclerosis Syndrome
    • 5.5.3.1. Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)

Chapter 6. Scleroderma Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class and Indication

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. Australia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. South Korea Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Scleroderma therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. F. Hoffman La-Roche Ltd
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Bristol-Myers Squibb Company
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Bayer AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Boehringer Ingelheim International GmbH
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Emerald Health Pharmaceuticals
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Sanofi
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Cytori Therapeutics Inc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Chemomab
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Corbus Pharmaceuticals Holdings, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Calliditas Therapeutics AB
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료